Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

A Phase 2, 3 Arm, Randomized, Double-Blind Study to Evaluate the Safety, PK and Efficacy of Proellex® Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids

To determine the safety, pharmacokinetics and efficacy of 4 doses (3, 6, 12, 24 mg) of Proellex in premenopausal women with uterine fibroids confirmed by ultrasound. Drug will be administered vaginally.

Study Overview

• Status: Completed
• Conditions: Uterine Fibroids
• Intervention / Treatment: Drug: Proellex

Detailed Description

This study is a phase II, 5 arm study with a 12 week active dosing period. The study will be conducted in 2 stages. In the first stage, the first 6 women to be enrolled will be treated at the 12mg dose level, and in addition to the other required study assessments will be monitored with a 24-hour PK assessment on Day 14, and daily trough assessments for the first 14 days. If, at Visit 3, the Cmax or AUC of any subject treated at 12mg exceeds the mean observed for the highest safe oral dose administered in the ZP-204 study, all subjects enrolled at the 12mg level will be discontinued, no further patients will be treated at this dose level, and the 6mg vaginal dose will be assessed in a similar fashion. In the second stage, the remaining subjects will be randomized to a dose of 3, 6, 12 or 24 mg.

For all subjects there will be a 4-6 week placebo run-in period, to establish baseline parameters (bleeding and quality of life) followed by treatment at one of three single-blind Proellex doses (3, 6 or 12 mg daily, administered vaginally in capsule form.) The primary efficacy endpoint will be bleeding assessed using the Pictorial Blood Loss Assessment Chart (PBAC) after 12 or 16 weeks of treatment. The secondary endpoints will be changes in size of uterine fibroids assessed by MRI and improvement in quality of life assessed using the Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire (UFSQOL0. Safety endpoints include significant adverse events, changes in physical examination results, and/or clinical laboratory results significantly outside of normal range. For subjects enrolled in Stage 2, PK will be assessed after the first and last doses and trough levels every 2 weeks.

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Florida
    • Miami Gardens, Florida, United States, 33169
      • Cetero Research
  • Texas
    • Houston, Texas, United States, 77030
      • Advances In Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 47 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Healthy adult females between 18 and 47 years of age with uterine fibroids confirmed by ultrasound.
• Normal transvaginal ultrasound (other than for presence of fibroids)
• History of menstrual events occurring in regular cycles
• Agreement not to attempt to become pregnant
• Agreement to limit alcohol consumption to no more than 2 drinks per week and to avoid alcohol consumption within 48 hours before each visit
• Ability to complete a daily subject diary
• Willing to discontinue hormonal contraceptives and consent to use of double barrier contraceptive techniques over the course of the study.
• Has a negative pregnancy test at the Screening and Baseline visits An exception for the pregnancy test requirement will be granted for subjects reporting surgical sterilization in medical history
• A Body Mass Index (BMI) between 18 and 39 inclusive
• Is available for all treatment and follow-up visits.

Exclusion Criteria:

• Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy
• Subject is pregnant or lactating or is attempting or expecting to become pregnant during the 6 month study period
• Women with abnormally high liver enzymes or liver disease. (ALT or AST exceeding 1.5xULN AND total bilirubin exceeding 1.5xULN at screening and confirmed on repeat).
• Received an investigational drug in the 30 days prior to the screening for this study
• Women with a history of PCOS
• Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study.
• Use of oral contraceptives in the preceding 2 weeks. Use of Depo-Provera® in the preceding 6 months.
• Has an IUD in place
• Women currently using narcotics
• Women currently taking spironolactone
• Infectious disease screen is positive for HIV or Hepatitis A, B or C
• Clinically significant abnormal findings on screening examination or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: SINGLE

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Proellex 12 mg PK group; Subjects receiving 12 mg Proellex administered vaginally, and completing a PK arm consisting of 1 x 24 hr PK of Proellex, 14 days of daily Proellex trough measurements, and 1 x 24 hr PK of Proellex after 14 days of daily dosing. 12 mg PK subjects will continue with the protocol as written after the first 2 week period and will be treated for a total of 16 weeks.	Drug: Proellex; vaginal suppository, daily, for 12 weeks; Other Names: Telapristone acetate
EXPERIMENTAL: Proellex 12 mg per protocol; Subjects receiving 12 mg Proellex daily, vaginally for 12 weeks	Drug: Proellex; vaginal suppository, daily, for 12 weeks; Other Names: Telapristone acetate
EXPERIMENTAL: Proellex 6 mg per protocol; Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks	Drug: Proellex; vaginal suppository, daily, for 12 weeks; Other Names: Telapristone acetate
EXPERIMENTAL: Proellex 3 mg per protocol; Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.	Drug: Proellex; vaginal suppository, daily, for 12 weeks; Other Names: Telapristone acetate
EXPERIMENTAL: 24 mg Proellex; 24 mg vaginal Proellex daily for 16 weeks	Drug: Proellex; vaginal suppository, daily, for 12 weeks; Other Names: Telapristone acetate

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Vaginal Bleeding	Change from baseline in vaginal bleeding assessed at the end of treatment (12 or 16 weeks) using a Pictorial Blood Loss Assessment Chart (PBAC), which measures volume (mL) of blood loss over a 28-day period Less blood loss represents an improvement.	12 or 16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood Levels of Proellex	Determination of Cmax of Proellex at end of treatment	12 or 16 weeks
Uterine Fibroid Size	Percent change in volume of confirmed uterine fibroids at end of treatment, assessed by MRI	12 or 16 weeks
Induction of Amenorrhea at End of Treatment	Percentage of subjects with induced amenorrhea during last 28 days on drug Amenorrhea was deemed to be achieved if no daily bleeding score was greater than 1 during the last 28 calendar days of the dosing period. A score of 1 was to be indicated if spotting was observed which did not require a sanitary product. Subjects that terminated early were deemed not to have achieved amenorrhea.	End of treatment
Endometrial Thickness	Percent change in median endometrial thickness from baseline to end of treatment assessed by ultrasound determination of uterine stripe.	12 or 16 weeks
Change in Quality of Life	Percentage change from baseline in median quality of life using uterine fibroid symptom and quality of life questionnaire (UFSQOL)	12 or 16 weeks

Collaborators and Investigators

• Sponsor: Repros Therapeutics Inc.
• Investigators: Study Director: Ronald D Wiehle, PhD, Repros Therapeutics Inc.

Publications and helpful links

Helpful Links

• Repros Therapeutics Inc corporate website

Study record dates

Study Major Dates

• Study Start: February 1, 2012
• Primary Completion (ACTUAL): December 1, 2012
• Study Completion (ACTUAL): January 1, 2013

Study Registration Dates

• First Submitted: October 11, 2011
• First Submitted That Met QC Criteria: October 11, 2011
• First Posted (ESTIMATE): October 13, 2011

Study Record Updates

• Last Update Posted (ESTIMATE): August 29, 2014
• Last Update Submitted That Met QC Criteria: August 8, 2014
• Last Verified: August 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Connective Tissue Diseases; Neoplasms, Connective Tissue; Neoplasms, Muscle Tissue; Leiomyoma; Myofibroma
• Other Study ID Numbers: ZPV-200